Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. INTC
3. ACN
4. SNY
5. DSX
6. GNK
7. ABBV
8. CART
9. DAL
10. AWK

Go back to Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1098.57 --0 (-0%)
Previous Close $1098.57    52 Week High $88.16 
Open $1098.57    52 Week Low $67.88 
Day High $1098.57    P/E 254.30 
Day Low $1098.57    EPS $4.32 
Volume 2,773